Tango Therapeutics TNGX Q1 2025 earnings
Reported May 12, 2025 · Before market open
Revenue$5.4MMiss by $967.3K
EPS-$0.36Miss by $0.02
Revenue estimate$6.4M
EPS estimate-$0.34
Next report
Aug 4, 2026 (In 6 days)Revenue estimate$1.6M
EPS estimate-$0.31
Financials
Q1 2025Valuation & ratios
Versus estimates
Revenue
Q3 2025$53.8MBeat by $53.3MQ2 2025$3.2MMiss by $3.2M
Q1 2025$5.4MMiss by $967.3K
Q4 2024$4.1MMiss by $3.9MDiluted EPS
Ask the moment Tango Therapeutics reports.
Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.
Connect your AI
Claude
Questions, answered.
- When did Tango Therapeutics report Q1 2025 earnings?
- Tango Therapeutics (TNGX) reported Q1 2025 earnings on May 12, 2025 before market open.
- What were Tango Therapeutics's Q1 2025 revenue and EPS?
- Tango Therapeutics reported revenue of $5.4M and eps of $-0.36 for Q1 2025.
- Did Tango Therapeutics beat estimates in Q1 2025?
- Revenue missed the consensus estimate of $6.4M by $967.3K. EPS missed the consensus estimate of $-0.34 by $0.02.
- How did Tango Therapeutics's Q1 2025 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 16.7% from $6.5M a year earlier and eps declined 2.9% from $-0.35.
- Where can I find Tango Therapeutics's Q1 2025 SEC filings?
- You can read the 10-Q periodic report (0000950170-25-068549) directly on SEC EDGAR. The filing index links above go to sec.gov.